

North Central Cancer Treatment Group

N078D, Phase I/II Trial of Rituximab, Cladribine, and Temsirolimus (RCT) Therapy in Newly Diagnosed Mantle Cell Lymphoma (MCL)

Revised Status Change – February 4, 2011

**NOTICE OF STATUS CHANGE**

The Phase I portion of this study will re-open to accrual for 3 patients at dose level 4 (Temsirolimus 25 mg, on days 1, 8 & 15) effective February 4, 2011.

NOTE: Local IRB approval of Addenda 8 & 9 is required prior to further patient enrollment.

**Please retain this notice with the protocol.**